BIOTECH
Zhuhai Essex Bio-Pharmaceutical Co., Ltd.
Zhuhai Essex Bio-Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") is an indirect wholly-owned subsidiary of Essex Bio-Technology Limited (stock code: 01061.HK). Founded in 1996, a high-tech enterprise focusing on R&D, manufacturing and commercialisation of genetically engineered therapeutic rb-bFGF (FGF-2).
The Company is located in the technological innovation coast of Zhuhai City, Guangdong Province. The corporate premises has a built-up area of approximately 20,000 square meters, integrated with GMP certified manufacturing facility, R&D centre, sales & marketing and other corporate functional units.. The Company has been awarded as one of "The Top 10 Pharmaceutical Enterprises of Guangdong Province in 2015","The Top 500 Manufacturing Enterprises of Guangdong Province in 2016" , "2019 TOP 100 Chinese Pharmaceutical Innovative Enterprises " and“2020 top 100 chemical pharmaceutical companies in the PRC”.
The products of the Company are principally prescribed for the treatment of wounds healing and diseases in Ophthalmology & Dermatology. Since 1998, there have been six commercialised biologics being marketed in China, namely “Beifushu”, “Beifuji” and “Beifuxin” product series, three of which are national category I drugs; “Beifuji” was approved for commercilisation in 1998 and known to be the first approved rb-bFGF drug globally then. “Beifushu”, “Beifuji” and “Beifuxin” are the leading brands in ophthalmology and surgical department (burns, dermatology, etc.).
The Company had undertaken the national "Ninth Five-Year" scientific and technological research, the National Torch Plan and the national major new drug development project. In recent years, it has established itself as “Guangdong Provincial Cytokine Engineering Technology Research Centre”, “Provincial Enterprise Technology Centre”, “Guangdong Provincial Ophthalmic Medicine Engineering Technology Research Center ", “Guangdong Province Aerosol Inhalation Formulation Engineering Technology Research Center ," “National Postdoctoral Research Station ", and the teaching and practice base of South China University of Technology and School of Pharmaceutical Sciences in Wenzhou Medical University.
In recognition of Company's great contributions in research and development of quality control standards and standard products in the field of biopharmaceutical drugs, as well as its key technical breakthrough, theory innovation and industrialization for protein drugs of cellular growth factor in China, in 2004 and 2018, the Company was honoured with the second prize of "National Scientific and Technology Progress Award" issued by the State Council.
With relentless R&D innovation efforts, the Company currently owns 38 patents, including 30 invention patents, 3 utility patents, 5 design patent, of which “rb-bFGF eye drops"and“rb-bFGF gel" were awarded one of the National Outstanding Innovation. Meanwhile, the Company owns 8 core products recognised as High-tech Products in Guangdong Province.
Leveraging on its in-house R&D platform in growth factor and antibody, the Company maintains a pipeline of projects in various clinical stages, covering a wide range of fields of indication.
Essex Medipharma (Zhuhai) Co., Ltd.
Essex Medipharma (Zhuhai) Co., Ltd. (hereinafter referred to as the "Company") is an indirect wholly-owned subsidiary of Essex Bio-Technology Limited (stock code: 01061.HK). Founded in 2001, the Company owns an extensive sales network and marketing system focusing on the sales and marketing of pharmaceuticals and medical devices.
The Company has built up a network of regional sales offices in major provinces and cities across China since 2003. After 18 years of continuous efforts, as at the end of 1H 2021, the Company’s products are marketed and sold through approximately 9,760 hospitals and 2,100 pharmaceutical stores in China, which are managed directly by its 43 regional sales offices with approximately 1,300 sales and marketing representatives.
The Company primarily provides sales and marketing services for the Group’s “Beifushu", "Beifuji", "Beifuxin" and single-dose eye drops series products. At present, "Beifushu", "Beifuji" and "Beifuxin" have been recognised as the leading brands of Ophthalmology and Dermatology, out of which, "Beifushu" is a renowned trademark in Guangdong Province, and its sales volume ranks the top in ophthalmic prescription drugs in China.
In addition, leveraging on its strong placement power in the field of ophthalmology and surgery in China, the Company also provides sales and marketing services for Pfizer's Xalatan & Xalacom, Shilishun (Iodized Lecithin Capsules), Yi Xue An Granules and other products.
Wuhan Adv.Dental Bio-Technology Co., Ltd.
Wuhan Adv.Dental Bio-Technology Co., Ltd.(hereinafter referred to as the "Company") became an indirect wholly-owned subsidiary of Essex Bio-Technology Ltd. (stock code: 01061.HK) since 2019 located in Jianghan Economic Development Zone, Wuhan City, Hubei Province.
The Company has long been committed to the technical innovation of oral minimally invasive medical products, a notable product developed from its technology platform, called Carisolv, is currently being marketed as its flagship product. Carisolv is being used to replace and/or combine with mechanical drill for treatment of caries.
The Company has built up strategic alliance with many international research institutions and dental experts in famous medical schools in China to develop a number of novel dental technology projects.
At a floor area of 1,200 square meters, the Company owns 10,000-level clean workshop, microbiology laboratories and physical & chemical laboratories, managed by a talented and competitive professional and management team, with extensive expertise in dental arena, Adv.Dental is focusing on delivering "innovative, high-efficient and high-quality" solutions to patients. promoting the concept of “Healthy life starts from teeth", bearing the ambition of improving the oral health and quality of life of people at large.
Zhuhai Essex Bio-Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") is an indirect wholly-owned subsidiary of Essex Bio-Technology Limited (stock code: 01061.HK). Founded in 1996, a high-tech enterprise focusing on R&D, manufacturing and commercialisation of genetically engineered therapeutic rb-bFGF (FGF-2).
The Company is located in the technological innovation coast of Zhuhai City, Guangdong Province. The corporate premises has a built-up area of approximately 20,000 square meters, integrated with GMP certified manufacturing facility, R&D centre, sales & marketing and other corporate functional units.. The Company has been awarded as one of "The Top 10 Pharmaceutical Enterprises of Guangdong Province in 2015","The Top 500 Manufacturing Enterprises of Guangdong Province in 2016" , "2019 TOP 100 Chinese Pharmaceutical Innovative Enterprises " and“2020 top 100 chemical pharmaceutical companies in the PRC”.
The products of the Company are principally prescribed for the treatment of wounds healing and diseases in Ophthalmology & Dermatology. Since 1998, there have been six commercialised biologics being marketed in China, namely “Beifushu”, “Beifuji” and “Beifuxin” product series, three of which are national category I drugs; “Beifuji” was approved for commercilisation in 1998 and known to be the first approved rb-bFGF drug globally then. “Beifushu”, “Beifuji” and “Beifuxin” are the leading brands in ophthalmology and surgical department (burns, dermatology, etc.).
The Company had undertaken the national "Ninth Five-Year" scientific and technological research, the National Torch Plan and the national major new drug development project. In recent years, it has established itself as “Guangdong Provincial Cytokine Engineering Technology Research Centre”, “Provincial Enterprise Technology Centre”, “Guangdong Provincial Ophthalmic Medicine Engineering Technology Research Center ", “Guangdong Province Aerosol Inhalation Formulation Engineering Technology Research Center ," “National Postdoctoral Research Station ", and the teaching and practice base of South China University of Technology and School of Pharmaceutical Sciences in Wenzhou Medical University.
In recognition of Company's great contributions in research and development of quality control standards and standard products in the field of biopharmaceutical drugs, as well as its key technical breakthrough, theory innovation and industrialization for protein drugs of cellular growth factor in China, in 2004 and 2018, the Company was honoured with the second prize of "National Scientific and Technology Progress Award" issued by the State Council.
With relentless R&D innovation efforts, the Company currently owns 38 patents, including 30 invention patents, 3 utility patents, 5 design patent, of which “rb-bFGF eye drops"and“rb-bFGF gel" were awarded one of the National Outstanding Innovation. Meanwhile, the Company owns 8 core products recognised as High-tech Products in Guangdong Province.
Leveraging on its in-house R&D platform in growth factor and antibody, the Company maintains a pipeline of projects in various clinical stages, covering a wide range of fields of indication.
Essex Medipharma (Zhuhai) Co., Ltd.
Essex Medipharma (Zhuhai) Co., Ltd. (hereinafter referred to as the "Company") is an indirect wholly-owned subsidiary of Essex Bio-Technology Limited (stock code: 01061.HK). Founded in 2001, the Company owns an extensive sales network and marketing system focusing on the sales and marketing of pharmaceuticals and medical devices.
The Company has built up a network of regional sales offices in major provinces and cities across China since 2003. After 18 years of continuous efforts, as at the end of 1H 2021, the Company’s products are marketed and sold through approximately 9,760 hospitals and 2,100 pharmaceutical stores in China, which are managed directly by its 43 regional sales offices with approximately 1,300 sales and marketing representatives.
The Company primarily provides sales and marketing services for the Group’s “Beifushu", "Beifuji", "Beifuxin" and single-dose eye drops series products. At present, "Beifushu", "Beifuji" and "Beifuxin" have been recognised as the leading brands of Ophthalmology and Dermatology, out of which, "Beifushu" is a renowned trademark in Guangdong Province, and its sales volume ranks the top in ophthalmic prescription drugs in China.
In addition, leveraging on its strong placement power in the field of ophthalmology and surgery in China, the Company also provides sales and marketing services for Pfizer's Xalatan & Xalacom, Shilishun (Iodized Lecithin Capsules), Yi Xue An Granules and other products.
Wuhan Adv.Dental Bio-Technology Co., Ltd.
Wuhan Adv.Dental Bio-Technology Co., Ltd.(hereinafter referred to as the "Company") became an indirect wholly-owned subsidiary of Essex Bio-Technology Ltd. (stock code: 01061.HK) since 2019 located in Jianghan Economic Development Zone, Wuhan City, Hubei Province.
The Company has long been committed to the technical innovation of oral minimally invasive medical products, a notable product developed from its technology platform, called Carisolv, is currently being marketed as its flagship product. Carisolv is being used to replace and/or combine with mechanical drill for treatment of caries.
The Company has built up strategic alliance with many international research institutions and dental experts in famous medical schools in China to develop a number of novel dental technology projects.
At a floor area of 1,200 square meters, the Company owns 10,000-level clean workshop, microbiology laboratories and physical & chemical laboratories, managed by a talented and competitive professional and management team, with extensive expertise in dental arena, Adv.Dental is focusing on delivering "innovative, high-efficient and high-quality" solutions to patients. promoting the concept of “Healthy life starts from teeth", bearing the ambition of improving the oral health and quality of life of people at large.
Essex
粤公网安备 44049102496184号